Curis (NASDAQ:CRIS) Stock Crosses Above 200-Day Moving Average of $1.78
Curis, Inc. (NASDAQ:CRIS)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.78 and traded as high as $2.01. Curis shares last traded at $1.98, with a volume of 1,376 shares traded.
Separately, ValuEngine lowered shares of Curis from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th.
The company’s 50 day simple moving average is $2.05 and its 200-day simple moving average is $1.78.
Several institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley increased its stake in Curis by 155.6% in the second quarter. Morgan Stanley now owns 19,564 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 11,911 shares during the last quarter. BlackRock Inc. lifted its position in Curis by 15.2% in the 2nd quarter. BlackRock Inc. now owns 487,816 shares of the biotechnology company’s stock worth $908,000 after buying an additional 64,262 shares during the last quarter. Renaissance Technologies LLC lifted its position in Curis by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,191,419 shares of the biotechnology company’s stock worth $2,216,000 after buying an additional 203,590 shares during the last quarter. Cetera Advisor Networks LLC bought a new stake in Curis in the 2nd quarter worth approximately $42,000. Finally, Fosun International Ltd boosted its stake in Curis by 46.6% in the second quarter. Fosun International Ltd now owns 581,834 shares of the biotechnology company’s stock worth $1,065,000 after buying an additional 184,965 shares in the last quarter. Hedge funds and other institutional investors own 23.64% of the company’s stock.
Curis Company Profile (NASDAQ:CRIS)
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
See Also: Street Name
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.